Treatment Information

Back

Lung Cancer treatment details. Chemotherapy, Biologic therapy.

University of North Carolina, Chapel Hill, N.C., United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Chapel Hill, N.C.
Treatments:Chemotherapy, Biologic therapyHospital:University of North Carolina
Drugs:Journal:Link
Date:Jun 2006

Description:

Patients: This Phase I/II trial involved a total of 26 patients with advanced non-small-cell lung cancer. There were 17 men and 9 women. The median age was 75.5.

Treatment: The treatment consisted of the chemotherapy drug Docetaxel and the biological therapy Gefitinib (Iressa) that inhibits an enzyme (tyrosine kinase).

Toxicity: There was one grade 5 pulmonary toxicity. Grade 3-4 toxicities included hematologic, gastrointestinal, dermatological, and infection.

Results: The median overall survival was 6.5 months.

Correspondence: Thomas E. Stinchcombe




Back